CO

Coloplast A/SCSE Coloplast Stock Report

Last reporting period 30 Sep, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

19.418

Large

Exchange

XCSE - Nasdaq Copenhagen A/S

COLO B.CO Stock Analysis

CO

Avoid

Based on Eyestock quantitative analysis, COLO B.CO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

49/100

Low score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

0.3 %

Undervalued

Market cap $B

19.418

Dividend yield

3.08 %

Shares outstanding

198 B

Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.

View Section: Eyestock Rating